KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.

Andrea Mari, Adam Stefanski, Daniel H van Raalte, Xiaosu Ma, Elizabeth S LaBell, Ludi Fan, Clare J Lee, Melissa K Thomas, Mathijs C Bunck, Ele Ferrannini

Diabetes Care 48(9) 1622-1627

PMID40694530
PMCIDPMC12368374
DOI10.2337/dc25-0763
发表日期2025-07-22
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

OBJECTIVE: We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks. RESEARCH DESIGN AND METHODS: This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline. Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests. RESULTS: At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia. In multivariate regression models, improvements in insulin sensitivity were associated mostly with weight reduction and partly with tirzepatide treatment, whereas enhancement in β-cell function was mostly associated with tirzepatide treatment. CONCLUSIONS: In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1 Changes in glucose AUC ( A ) and insulin AUC ( B ) at week 72 from baseline for the overall SURMOUNT-1 study population and by glycemic status at baseline. Data are least-squares (LS) mean ± SE. For both outcomes, changes were significantly greater with tirzepatide compared with placebo, irrespective of glycemic status ( P < 0.001).
非 KM Figure
Figure 2Figure 2 Changes in modeled β-GS ( A ) and ISR at 5.4 mmol/L glucose ( B ) at week 72 from baseline for the overall SURMOUNT-1 study population and by glycemic status at baseline. Data are least-squares (LS) mean ± SE. For both outcomes, changes were significantly greater for all tirzepatide groups compared with placebo, irrespective of glycemic status ( P < 0.05), except for β-GS in participants with prediabetes treated with tirzepatide 5 mg ( P = ns).
非 KM Figure
Figure 3Figure 3 Changes in the Matsuda index ( A ) and OGIS ( B ) at week 72 from baseline for the overall SURMOUNT-1 study population and by glycemic status at baseline. Data are least-squares (LS) mean ± SE. For both outcomes, changes were significantly greater with tirzepatide compared with placebo, irrespective of glycemic status ( P < 0.001).
非 KM Figure